Open AccessIs New‐Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?—Con
Author(s) -
Moser Marvin
Publication year - 2006
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2005.04594.x
Subject(s) - medicine , diabetes mellitus , nod , clinical significance , angiotensin receptor blockers , clinical trial , renin–angiotensin system , endocrinology , intensive care medicine , blood pressure
There is little doubt that diabetes is more common in hypertensive than normotensive individuals. There are also some data suggesting that the use of certain antihypertensive agents, i.e., diuretics and more specifically some β blockers will increase the occurrence of new onset diabetes (NOD) when compared to other medications, especially angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers. The clinical significance of this l%–3.5% difference, however, has not been established. Different studies report different outcomes. In large outcome trials the occurrence of NOD did not effect mortality or morbidity outcomes. Although one study reported that NOD had the same prognosis as pretreatment diabetes, another did not. At present, data are insufficient to suggest that NOD is of important clinical significance or that present treatment recommendations, especially regarding the use of diuretics, should be changed.